Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
120,781,538
-
Total 13F shares
-
92,968,604
-
Share change
-
+4,200,214
-
Total reported value
-
$347,619,918
-
Put/Call ratio
-
199%
-
Price per share
-
$3.74
-
Number of holders
-
168
-
Value change
-
+$14,526,156
-
Number of buys
-
100
-
Number of sells
-
80
Institutional Holders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) as of Q3 2023
As of 30 Sep 2023,
Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) was held by
168 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
92,968,604 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, Temasek Holdings (Private) Ltd, JPMORGAN CHASE & CO, MORGAN STANLEY, Kohlberg Kravis Roberts & Co. L.P., CITADEL ADVISORS LLC, BARCLAYS PLC, and Aristotle Capital Boston, LLC.
This page lists
168
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.